PETER KOTANKO, M.D.
Osteopathic Medicine at 96 St, New York, NY
License number
New York 262949
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
175 E 96Th St APT 21L, New York, NY 10128
Phone
(917) 428-1957
Personal information
See more information about PETER KOTANKO at radaris.comName
Address
Phone
175 E 96Th St APT 21L, New York, NY 10128
175 E 96Th St, New York, NY 10128
Professional information
Research Director At Renal Research Institute
Position:
Research Director at Renal Research Institute
Location:
New York, New York
Industry:
Research
Work:
Renal Research Institute
- New York City since Oct 2007
-
Research Director
Krankenhaus Barmherzige Brueder Graz, Austria
Jun 1989 - Oct 2007
-
Vice Chair, Department of Internal Medicine
Medical University Innsbuck, Austria
Apr 1982 - Jun 1989
-
Assistant Professor
Education:
London University, UK 1995 - 1996
Diploma in Nephrology, Nephrology University Padua, Italy 1983 - 1983
Medical University Innsbruck, Austria 1976 - 1982
MD, Medicine BG und BRG Braunau 1968 - 1975
Diploma in Nephrology, Nephrology University Padua, Italy 1983 - 1983
Medical University Innsbruck, Austria 1976 - 1982
MD, Medicine BG und BRG Braunau 1968 - 1975
System And Method Of Identifying When A Patient Undergoing Hemodialysis Is At Increased Risk Of Death By A Logistic Regression Model
US Patent:
2013004, Feb 14, 2013
Filed:
Apr 22, 2011
Appl. No.:
13/642364
Inventors:
Peter Kotanko - New York NY, US
Stephan Thijssen - New York NY, US
Len Usvyat - Philadelphia PA, US
Nathan W. Levin - New York NY, US
Stephan Thijssen - New York NY, US
Len Usvyat - Philadelphia PA, US
Nathan W. Levin - New York NY, US
International Classification:
G06Q 50/22
US Classification:
705 2
Abstract:
Identifying a patient undergoing periodic hemodialysis treatments at increased risk of death by a logistic regression model includes selecting one or more clinical or biochemical parameter parameters associated with a probability of death of the patient while the patient is undergoing periodic hemodialysis treatments, and estimating the probability of death of the patient over a future time interval by a logistic regression model including model coefficients, the model coefficients determined by analyzing data from deceased patients that were previously undergoing periodic hemodialysis treatments, the analysis including a longitudinal analysis backwards in time on the one or more clinical or biochemical parameters of the deceased patients. The patient is identified as having an increased risk of death if the probability of death of the patient is greater than a predetermined threshold probability.
Method Of Identifying When A Patient Undergoing Hemodialysis Is At Increased Risk Of Death
US Patent:
2013024, Sep 19, 2013
Filed:
Dec 1, 2011
Appl. No.:
13/989370
Inventors:
Peter Kotanko - New York NY, US
Stephan Thijssen - New York NY, US
Len Usvyat - Philadelphia PA, US
Nathan W. Levin - New York NY, US
Stephan Thijssen - New York NY, US
Len Usvyat - Philadelphia PA, US
Nathan W. Levin - New York NY, US
International Classification:
G01N 33/50
US Classification:
435 15, 436 74, 436 79, 436 66, 436105, 435 39, 436 86, 436 87, 436 98, 436 63
Abstract:
The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.
Method Of Identifying When A Patient Undergoing Hemodialysis Is At Increased Risk Of Death
US Patent:
2011013, Jun 9, 2011
Filed:
Dec 2, 2010
Appl. No.:
12/959017
Inventors:
Peter Kotanko - New York NY, US
Stephan Thijssen - New York NY, US
Len Usvyat - Philadelphia PA, US
Nathan W. Levin - New York NY, US
Stephan Thijssen - New York NY, US
Len Usvyat - Philadelphia PA, US
Nathan W. Levin - New York NY, US
Assignee:
Fresenius Medical Care Holdings, Inc. - Waltham MA
International Classification:
A61B 5/00, G06Q 50/00
US Classification:
600301, 705 3
Abstract:
The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, including systolic blood pressure, serum albumin concentration level, body weight, body temperature, serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.
Methods Of Regional Citrate Anticoagulation Dialysis
US Patent:
2011023, Sep 29, 2011
Filed:
Jun 17, 2010
Appl. No.:
12/817390
Inventors:
Peter Kotanko - New York NY, US
Stephan Thijssen - New York NY, US
Nathan W. Levin - New York NY, US
Stephan Thijssen - New York NY, US
Nathan W. Levin - New York NY, US
Assignee:
Fresenius Medical Care Holdings, Inc. - Waltham MA
International Classification:
A61M 1/16
US Classification:
604 607
Abstract:
A method of performing regional citrate anticoagulant dialysis of a patient's blood includes flowing blood from and back to the patient through an extracorporeal circuit including a dialyzer having semi-permeable dialysis membranes and a dialysate chamber surrounding the membranes. The method further includes flowing a dialysate containing calcium and citrate through the dialysate chamber of the dialyzer and introducing citrate into the patient's blood upstream of the dialyzer, whereby the patient's blood is dialyzed. The method can further include predicting the concentration of systemic ionized calcium in the blood of the patient at any point in the dialysis treatment or post-dialysis, such as by a mathematical model. The method can further include statistically correcting the preliminary predicted post-dialysis concentration of systemic ionized calcium in the patient's blood to provide a final predicted post-dialysis systemic ionized calcium concentration. The method can further include statistically correcting the preliminary predicted systemic ionized calcium concentration for any time point during the dialysis treatment to provide a final predicted systemic ionized calcium concentration for that time point.
Method Of Identifying When A Patient Undergoing Hemodialysis Is At Increased Risk Of Death
US Patent:
2010009, Apr 22, 2010
Filed:
Oct 15, 2009
Appl. No.:
12/587941
Inventors:
Peter Kotanko - New York NY, US
Stephan Thijssen - New York NY, US
Len Usvyat - Philadelphia PA, US
Nathan W. Levin - New York NY, US
Stephan Thijssen - New York NY, US
Len Usvyat - Philadelphia PA, US
Nathan W. Levin - New York NY, US
Assignee:
Fresenius Medical Care Holdings Inc. - Waltham MA
International Classification:
A61B 5/00
US Classification:
600301
Abstract:
The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a substantial change in the rate of decline of at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data in deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a substantial change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.
Method Of Determining A Phosphorus Binder Dosage For A Dialysis Patient
US Patent:
2010009, Apr 22, 2010
Filed:
Oct 16, 2009
Appl. No.:
12/580803
Inventors:
Frank A. Gotch - San Francisco CA, US
Benjamin J. Lipps - Boston MA, US
Peter Kotanko - New York NY, US
Nathan W. Levin - New York NY, US
Amanda K. Stennett - Waltham MA, US
Norman J. Ofsthun - Lexington MA, US
Benjamin J. Lipps - Boston MA, US
Peter Kotanko - New York NY, US
Nathan W. Levin - New York NY, US
Amanda K. Stennett - Waltham MA, US
Norman J. Ofsthun - Lexington MA, US
Assignee:
Fresenius Medical Care Holdings, Inc. - Waltham MA
International Classification:
B01D 61/34
US Classification:
210647
Abstract:
The invention is directed to a method of determining a dosage of phosphorus binder for a patient undergoing dialysis treatment to achieve a pre-dialysis serum phosphorus concentration within a desired concentration range while achieving a desired net accumulation of calcium. The method includes determining the dosage of phosphorus binder that will achieve pre-dialysis serum phosphorus concentration of the patient that is within the desired concentration range while accounting for the change in the amount of phosphorus removed by the dialysis treatment when the pre-dialysis serum phosphorus concentration of the patient is within the desired concentration range, determining a dialysate calcium concentration that will result in the desired net accumulation of calcium over a complete dialysis cycle, and dialyzing the patient with a dialysate containing a calcium concentration based upon that determination.
Method Of Removing Protein-Bound Deleterious Substances During Extracorporeal Renal Replacement Treatment
US Patent:
8206591, Jun 26, 2012
Filed:
Oct 15, 2009
Appl. No.:
12/579909
Inventors:
Peter Kotanko - New York NY, US
Nathan W. Levin - New York NY, US
Nathan W. Levin - New York NY, US
Assignee:
Fresenius Medical Care Holdings, Inc. - Waltham MA
International Classification:
B01D 61/26, B01D 61/24, B01D 61/30, A61M 1/34
US Classification:
210638, 210644, 210645, 210646, 210660, 604 401, 604 501, 604 504, 604 609, 604 29
Abstract:
The invention is directed to a method of removing a deleterious substance bound to a protein in blood of a patient by introducing a displacer substance into the blood under conditions in which the displacer substance replaces deleterious substance bound to the protein, thereby resulting in additional unbound deleterious substance in the blood, and removing unbound deleterious substance from the blood by extracorporeal renal replacement treatment.
Method Of Controlling Diffusive Sodium Transport In Dialysis
US Patent:
8518260, Aug 27, 2013
Filed:
Oct 1, 2010
Appl. No.:
12/896009
Inventors:
Jochen G. Raimann - New York NY, US
Erik Lars Penne - Amsterdam, NL
Stephan Thijssen - New York NY, US
Peter Kotanko - New York NY, US
Nathan W. Levin - New York NY, US
Erik Lars Penne - Amsterdam, NL
Stephan Thijssen - New York NY, US
Peter Kotanko - New York NY, US
Nathan W. Levin - New York NY, US
Assignee:
Fresenius Medical Care Holdings, Inc. - Waltham MA
International Classification:
B01D 61/32, B01D 61/24, B01D 61/30
US Classification:
210647, 210645, 210646, 210739, 604 401, 604 504, 604 28
Abstract:
A method of controlling diffusive sodium transport from the dialysate solution to the blood of a patient undergoing hemodialysis treatment or from the blood to the dialysate solution includes calculating SNa, an average of the patient's historic serum sodium concentrations, and estimating SNa, the patient's pre-dialysis serum sodium concentration, based on the average of the patient's measured historic pre-dialysis serum sodium concentrations, SNa. The method enables adjusting DNa, the sodium concentration of the dialysate solution, based on the average of the patient's historic serum sodium concentrations, SNa, if needed, and performing the dialysis treatment of the patient using a dialysate solution containing a sodium concentration DNa.
Method Of Removing Protein-Bound Deleterious Substances During Extracorporeal Renal Replacement Treatment
US Patent:
2012025, Oct 4, 2012
Filed:
Jun 12, 2012
Appl. No.:
13/494506
Inventors:
Peter Kotanko - New York NY, US
Nathan W. Levin - New York NY, US
Nathan W. Levin - New York NY, US
Assignee:
Fresenius Medical Care Holdings, Inc. - Waltham MA
International Classification:
C07K 1/14
US Classification:
530392, 530402, 530409
Abstract:
The invention is directed to a method of removing a deleterious substance bound to a protein in blood of a patient by introducing a displacer substance into the blood under conditions in which the displacer substance replaces deleterious substance bound to the protein, thereby resulting in additional unbound deleterious substance in the blood, and removing unbound deleterious substance from the blood by extracorporeal renal replacement treatment.